Tandem disclosed on August 7, 2025, that a malfunction had been identified in some of its insulin pumps, which could "trigger an error resulting in a discontinuation of insulin delivery," which "could result in hyperglycemia due to discontinuation of insulin delivery" and "may require hospitalization or intervention from a medical professional." Tandem stated that it had sent notices to impacted customers between July 22 and 24, 2025.
Following this news, Tandem's stock price dropped.
To receive more information, please fill out the form.
